P-53 has been called the guardian of the genome for the cell.

She called me on the cell phone to tell me what she's found.

These proteins mimic known host proteins in the cell in a very interesting way.

I tied the rope around me and called up, if somebody had a cell phone, to call my sister and tell her I was OK. I didn't want her hearing about it on the news. We're very close.

We all understood why they called the game. If that happened to one of our players, we wouldn't have really had the mindset to play -- we wouldn't have even cared -- so I'm glad they didn't make the Crimson Tide players go through that. It was understandable, and we had no problem with it. It was the right decision.

It all started here at M. D. Anderson with the concept, vector development, preclinical trials and the first phase of testing. This agent has clinical benefit, and because of its novelty and lack of interest by major pharmaceutical companies, the only way to make it available to patients was to start a biotech company. But it has been a long road.